EVI1 is an oncogene frequently associated with chronic and acute myeloid leukemia. In hematopoietic cells, EVI1 impairs several pathways including proliferation, differentiation, and apoptosis. Interferon-␣ (IFN-␣) is a powerful cytokine that controls the immune response and limits the expansion of several tissues including bone marrow. These properties contribute to the effectiveness of IFN-␣ in the treatment of many neoplastic disorders especially chronic myeloid leukemia. We report here that in murine hematopoietic progenitors the expression of EVI1 completely abrogates the antiproliferative and apoptotic effects of IFN-␣. EVI1 does not repress the JAK/STAT signaling pathway or the activation of many IFN-responsive genes. On the contrary, EVI1 prolongs the phosphorylation of STAT1 and the activation of an IFN-dependent reporter gene. However, EVI1 specifically represses the IFN-dependent induction of the tumor suppressor PML and blocks the apoptotic pathways activated by PML. We show that the position of the ISRE, which is located within the first exon of PML, is critical to block PML induction by IFN-␣. The relocation of the ISRE to a position upstream of the transcription start site is sufficient to re-establish the response to IFN in the presence of EVI1. Our data suggest that stabilized STAT1 phosphorylation and prolonged binding of the STAT1 complex to the first exon could impair PML transcription and inhibit the activation of PML-dependent apoptotic pathways resulting in loss of IFN response. These results point to a novel mechanism utilized by an oncogene to escape normal cell response to growth-controlling cytokines.
EVI1 was identified as the integration site of an activating ecotropic retrovirus leading to acute myeloid leukemia in susceptible strains of mice (1) . EVI1 has been associated with human chronic myeloid leukemia, myelodysplastic syndrome, acute myeloid leukemia, and with aggressive solid tumors including lung and endometrial cancers (2) (3) (4) (5) (6) (7) . Recently the causative association between EVI1 and myelodysplastic syndrome was confirmed in a mouse model (8) . EVI1 exists also in a longer form called MDS1/EVI1 that includes a methyltransferase-like SET domain at the N terminus. This form is independently regulated and transcribed from an upstream promoter and has not been associated with neoplastic transformation (9 -11) . MDS1/EVI1 belongs to the PR-domain family of proteins, which includes 16 members characterized by zinc finger domains and by a SET domain (12, 13) . Several members of this family also exist in the shorter form that lacks the SET domain like EVI1 and which has been associated with solid and hematopoietic cancers (14 -18) . EVI1 is a nuclear transcription repressor with 2 domains of 7 and 3 zinc finger motifs that bind to DNA in vitro (4, 19 -21) . EVI1 interacts with co-repressors and co-activators of which are also reversibly acetylated (22) . A striking feature of EVI1 is its ability to strongly accelerate cell cycle and proliferation by interacting with BRG1, a member of the SWI/SNF chromatin-remodeling complex (23) . The expression of EVI1 in hematopoietic cells abrogates the growth-inhibitory effect of transforming growth-␤, a regulator of hematopoietic cell expansion, by interaction with SMAD3 and the inactivation of SMAD signaling (24, 25) .
IFN-␣ 1 belongs to a cytokine family that exhibits antiviral properties, immunomodulating effects, and antiproliferative activity on normal and transformed cells (26) . These diverse properties are mediated through binding to a high affinity cell surface receptor that in turn activates a variety of intracellular signals and modulates gene expression and apoptosis (27) (28) (29) (30) . In a very simplified view, IFN-␣ binds to the Type I IFN membrane receptor inducing its dimerization and the activation of two Janus family tyrosine kinases, TYK-2 and JAK-1, which leads to activation and homo-or heterodimerization of the signal transducers and activators of transcription (STAT) proteins (most frequently STAT1 and STAT2 for the IFN-␣ pathway). The activated STAT1-STAT2 dimer interacts with p48 to form the mature ISGF3 complex that translocates to the nucleus and activates transcription of IFN-stimulated genes (ISGs) by binding to the IFN-␣-stimulated response elements (ISRE) in their promoter (27) (28) (29) . The activation of the IFN-␣ pathway leads to the expression of literally hundreds of ISGs, many of which are activated in a tissue-specific fashion. The tumor suppressor PML and several components of the PML bodies, including SP100, are up-regulated by IFN-␣ in almost all cell types (31) (32) (33) . This up-regulation leads to a noticeable increase in the number of the PML nuclear bodies, which have been implicated in the control of several apoptotic pathways (34, 35) . The direct role of PML in growth arrest and apoptosis induced by IFN-␣ was later confirmed by showing that cells with biallelic inactivation of Pml are unresponsive to IFN-␣ (34) . In general, the gene-activating effects of IFN-␣ last about 5 h (29, 36 -38) . The mechanisms that regulate the inactivation of the ISGF3 complex are less clear. Several phosphatases have been implicated in this process but as yet no single enzyme has been clearly demonstrated to be universally involved in part because many of these enzymes seem to be cell type-specific (39, 40) . Here we have examined the role of EVI1 in the IFN-␣ response and found that EVI1 blocks the inhibitory effect of IFN-␣ in normal murine bone marrow (BM) cells and cell lines. EVI1 does not affect the signaling pathway of IFN-␣ or the assembly of the activated ISGF3 complex, which efficiently binds to the DNA in cells that express EVI1. The expression of many ISGs we tested is not altered by EVI1 and we find, rather surprisingly, that in the presence of EVI1 the phosphorylation of STAT1 and the consequent activation of an IFN-responsive reporter gene are actually and significantly prolonged. However, we also find that among all the IFN-responsive genes we tested, only Pml is not induced above basal level as expected when EVI1 is expressed and, as a consequence, we find that Pml-depending apoptotic pathways are not activated. A difference between the PML promoter and those of other IFN-responsive genes is the position of the ISRE, which in PML occurs uniquely within the first exon (33) . Mutation analyses of the PML promoter and that of an IFN-responsive gene unaffected by EVI1 confirm that the position of the ISRE is critical to the abrogation of the IFN response by EVI1. We conclude that EVI1 inhibits the IFN response by selectively repressing proapoptotic genes that, like PML, contain the ISRE in their transcribed sequence. Our data point at a novel mechanism that is exploited by oncogenes to escape cytokine-dependent control of cell proliferation.
EXPERIMENTAL PROCEDURES
DNA Constructs-The plasmid FLAG-EVI1 used in reporter gene assays has been previously described (22) . HA-EVI1 was cloned in the EcoRI and BamHI restriction site of the MSCV vector (Clontech, San Jose, CA). The human WT ISG15 promoter from nucleotide Ϫ121 to ϩ21 was amplified by genomic PCR and cloned in the HindIII and XhoI restriction sites of the promoterless luciferase reporter pGL3-basic vector (Promega, Madison, WI). The mutant ISG15 promoter ISRE was constructed by PCR of genomic DNA with a 5Ј primer that starts at nucleotide Ϫ86 of the normal promoter and a 3Ј primer that anneals to nucleotide ϩ21 and contains an extension identical to the region Ϫ121 to Ϫ86 that spans the ISRE of the WT ISG15 promoter. The sequence of the 3Ј extension is Ϫ121 CATGCCTCGGGAAAGGGAAAC-CGAAACTGAAGCCAA Ϫ86 , where the ISG15 ISRE consensus site is indicated in bold. Therefore this mutant promoter is identical to the WT promoter but the ISRE and flanking nucleotides have been repositioned from nucleotides Ϫ121 to Ϫ86 to nucleotides ϩ21 to ϩ56. After cloning, the WT and mutant ISG15 promoters were sequenced. The human WT PML promoter was constructed with the same strategy using genomic PCR from nucleotide Ϫ157 to nucleotide ϩ58. The fragment was cloned in the HindIII and XhoI restriction sites of pGL3-basic vector (Promega, Madison, WI). PML-ISRE mutant promoter was constructed by PCR with a 5Ј primer containing the extension ϩ31 ATCTAAACCGAGAATC-GAAACTAAGCTG ϩ58 in which the PML ISRE consensus site is indicated in bold. Both plasmids were verified by DNA sequencing.
Cell Culture and Murine BM Progenitors Culture-The maintenance, transfection, and culture of the retroviral producer cell line Phoenix (ATCC) have been reported (22, 41) . The infection, selection, culture, and differentiation of murine BM progenitors infected with the empty MSCV retrovirus or MSCV-HA-EVI1 were carried out as described (41) . EVI1-expressing SiHa stable lines were generated by calcium phosphate transfection with either the pCMV vector (vector-SiHa) or pCMVFlag-EVI1 (EVI1-SiHa) and selection with neomycin. For reporter gene assays, cell lines were transfected with the appropriate reporter gene and either the vector pCMV or pCMV-Flag-EVI1 and were maintained in Dulbecco's modified minimum essential medium supplemented with 10% newborn calf serum (Invitrogen, Carlsbad, CA).
RNA Isolation and cDNA Preparation-Total cellular RNA was extracted as described (42 (42) . The primers and probes for murine GAPDH were purchased (Applied Biosystem, Foster City, CA). The primers and probe used for murine Pml were: forward, AACCCT-GCGCTGACTGACAT, and reverse, GTGCCTAGTTCCTCATGCCACT; the probe was CAACCACAGCCATCTCCATTGCGA. The probe was labeled by a 5Ј FAM reporter and a 3Ј TAMRA quencher. The primers and probe were designed using Primer Express software (Applied Biosystem, Foster City, CA). RQ-PCR amplification was performed on the iCycler iQ detection system (Bio-Rad), and the data were collected and analyzed using iCycler iQ version 3.1 software.
Apoptosis Gene Expression Profiling System-The human cDNA expression array GEArray TM Q Apoptosis (SuperArray Bioscience Corp., Frederick, MD) was used for the evaluation of 96 genes with known apoptotic function. The experiment was performed according to the manufacturer's protocols.
Western Blot and Northern Blot Analyses-Cell lysate of mouse hematopoietic progenitors infected either with MSCV empty vector or MSCV-HA-EVI1 were quantified and Western blot analyses were performed as described (43) . Ten g of total RNA isolated from vector-or EVI1-SiHa cells was used to perform the Northern blot assay as reported (19) .
Electrophoretic Mobility Shift Assays (EMSA)-Fifteen g of nuclear extract of vector-or EVI1-SiHa cells were incubated at room temperature for 30 min with 32 P-labeled double-stranded oligonucleotide probe containing the ISG15 or PML ISRE-binding sites. The samples were separated by electrophoresis on a 0.5 M Tris-borate-EDTA nondenaturing 4% polyacrylamide gel at 140 V for 2 h and autoradiographed overnight as described (33) .
Reporter Gene Studies-The reporter gene assays were performed as reported (41) .
Immunofluorescence-The vector-or EVI1-hematopoietic BM cells were washed three times with phosphate-buffered saline and fixed in 4% paraformaldehyde in phosphate-buffered saline for 20 min. The cell membrane was permeabilized by treatment with 50% methanol and 50% acetone at Ϫ20°C for 7 min. The cells were washed with phosphate-buffered saline, and nonspecific antibody binding was blocked with 5% normal bovine serum (Sigma). The cells were treated with goat polyclonal anti-PML antibody (Santa Cruz, Santa Cruz, CA) at a dilution 1:1000 for 1 h. After washing with phosphatebuffered saline, the cells were stained with donkey anti-goat Alexa Fluor® 594 (Molecular Probes, Eugene, OR) at a dilution 1:5000 for 1 h. The cells were washed, stained with 4,6-diamidino-2-phenylindole, and treated with a prolonged anti-fading medium (Molecular Probes). The proteins were visualized with immunofluorescence microscopy (Zeiss Inc., Thornwood, NY).
ELISA-The ELISA to evaluate the STAT1 phosphorylation was performed according to the manufacturer's protocol TransAM (Active Motif, Carlsbad, CA).
RESULTS

EVI1
Abrogates IFN-␣ Growth Suppression in Normal Murine BM Lineage-negative Cells-To determine whether the expression of EVI1 affects the response of primary cells to
EVI1 Blocks IFN
IFN-␣, we used normal murine BM cells because they are highly sensitive to IFN-␣ and undergo growth arrest and apoptosis when cultured with this cytokine. After isolation of the BM from healthy 5-week-old mice, lineage-negative progenitors were selected and infected with recombinant retroviruses expressing EVI1 or with the empty vector by spinoculation as we described (41) . To eliminate non-infected cells, 150,000 cells were plated in methylcellulose-based medium and cultured with G418 (41). After 7 days of culture, several colonies were clearly visible in each plate. The colonies were isolated from the methylcellulose, disaggregated, and 15,000 cells were plated in duplicate in the absence or presence of IFN-␣. EVI1 is a protein with an apparent mass of about 145 kDa. The diagram of EVI1 and the expression of the protein in the BM cells are shown in Fig. 1 , A and B. In the absence of IFN-␣, the BM cells proliferated and produced colonies. As we also reported earlier (8), EVI1-positive BM progenitors have a much higher plating efficiency and generate about 2 times more colonies than the control progenitor cells (Table I ). The most striking difference between vector and EVI1 cells was observed when the BM cells were cultured with IFN-␣. As expected, the vector BM cells formed very small and sparse colonies when they were cultured with IFN-␣ and the cells did not survive after 7 days of culture. In contrast, EVI1-positive cells were completely unresponsive to IFN-␣ and the number of the colonies was not statistically different in the presence or absence of the cytokine (Table I) .
EVI1 Does Not Affect the JAK/STAT Pathway of the DNA Binding of the ISGF3
Complex-Our studies indicate that EVI1 expression in mouse BM cells abrogates the antiproliferative and pro-apoptotic effects of IFN-␣. Therefore, we determined whether this effect is because of down-regulation of the IFN-activated JAK/STAT pathway. The phosphorylation of STAT1 on tyrosine 701 is a critical early step required for interaction with STAT2 and translocation to the nucleus (26 -29) . To determine whether tyrosine 701 phosphorylation is affected in normal mouse BM cells expressing EVI1, mouse progenitor cells infected either with empty retroviral vector or EVI1 retrovirus were treated with IFN-␣. Total cell lysates were analyzed by SDS-PAGE and immunoblotted with an antibody that recognizes STAT1 phosphorylation on tyrosine 701. Tyrosine phosphorylation of STAT1 was inducible in the murine progenitors independently of whether EVI1 was expressed (Fig. 1C) . To determine whether EVI1 affects the DNA binding of ISGF3 to the ISRE consensus we carried out EMSA with a DNA probe corresponding to the ISRE sequence of ISG15 (33) using the nuclear extract of human SiHa cells stably transfected either with empty retrovirus (vector-SiHa) or EVI1 retrovirus (EVI1-SiHa). We chose the ISRE of the ISG15 promoter because this sequence is routinely used as probe for this type of assay (33, 36, 37) . The assays were performed with cells cultured in the absence or presence of human IFN-␣. We found that EVI1 itself does not noticeably bind to the probe (Fig. 1D, lane 3) . In addition, as expected (33), we confirmed that the ISGF3 complex binds to the probe inducing the appearance of a new slowmigrating band in IFN-␣-treated cells (Fig. 1D, lane 2) . A more intense band with identical migration rate appears in IFN-␣-treated cells transfected with EVI1 (Fig. 1D, lane 4) , indicating that EVI1 does not inhibit the formation of the DNA-ISGF3 complex. This band is not visible in EVI1-SiHa in the absence of IFN treatment, indicating that the band in lane 4 is generated by the IFN-activated ISGF3 complex. To determine whether IFN treatment affects expression of EVI1 or STAT1, we analyzed by Western blot the stably transfected vector-and EVI1-SiHa cell lines. The results (Fig. 1E) indicate that IFN-␣ does not appreciably alter the steady-state level of these proteins.
EVI1 Does Not Preclude the Response of Many ISGs but Prevents the Up-regulation of PML in Response to IFN-␣-Even
though the activation and DNA binding of ISGF3 do not appear altered by EVI1, we compared the expression of a panel of IFN-activated ISGs to determine whether EVI1 affects their induction in other ways. For these assays we used RT-PCR analysis of vector-and EVI1-SiHa stably transfected cell lines. We isolated total RNA from vector-and EVI1-SiHa cells treated with IFN-␣ or untreated. The RNA was reverse transcribed and used in RT-PCR assays with GAPDH as control. The genes we analyzed were CXCL10, GBP1, IFI27, IFI35, IFIT1, IRF7, ISG20, MX2, OAS1, IRF1, ISG54, ISG15, and PML. These genes are those most frequently analyzed to evaluate the response to IFN-␣ (44). As expected (27) (28) (29) , these genes were activated by IFN-␣ in vector cells ( Fig. 2A, top) . However, we also found that their activation was unperturbed and not appreciably changed in the presence of EVI1 ( Fig. 2A,  bottom) . The RT-PCR result of ISG15 was confirmed by Northern blot analysis (Fig. 2B ). Among this group of genes, the only one that was not activated when EVI1 was expressed was PML ( Fig. 2A , PML, top and bottom panels). To confirm that EVI1 blocks the up-regulation of Pml also in normal cells, we used RQ-PCR analysis of freshly harvested murine BM cells infected and selected as described, and we cultured the cells for 12 h in the presence or absence of IFN-␣. The expression of Pml was normalized to Gapdh. The results show that in vector cells the expression of Pml is increased about 23-fold in response to IFN-␣ (Fig. 3A , from 27 to 681 arbitrary normalized units). In contrast, Pml is up-regulated less than 5-fold in EVI1-positive cells (Fig. 3A , from 24 to 114 arbitrary normalized units). It is well known that a consequence of exposure to IFN-␣ is the up-regulation of PML and an increase of nuclear PML bodies (31) (32) (33) . To determine whether the loss of Pml transcription in the presence of EVI1 correlates with a loss of induction of Pml bodies, we cultured normal murine BM cells infected with the empty retroviral vector or EVI1 retrovirus in the absence or presence of IFN-␣ and analyzed the cells by immunofluorescence. After 24 h, the cells were fixed on slides and Pml bodies were visualized as described under "Experimental Procedures" (Fig. 3B) . The nuclei were identified by 4,6-diamidino-2-phenylindole staining. As previously described (30, 32, 33) , the immunofluorescence assays show a remarkable correlation between the increase of Pml bodies in cells that respond to IFN-␣ (Fig. 3B, vector) . However, such an increase was not seen in EVI1-positive cells that were unresponsive to IFN-␣ (Fig. 3B,  EVI1 ). Taken together, these results suggest that EVI1 does not prevent the up-regulation of the vast majority of IFNresponsive genes we tested and that PML appears to have a unique response among them. Furthermore, because the PML bodies control many cellular functions and have been associated with PML-dependent apoptotic pathways (34, 35 ) the results also suggest that EVI1 could block the antiproliferative and pro-apoptotic effects of IFN-␣ by preventing the activation of PML-dependent apoptotic pathways.
EVI1 Blocks Apoptosis Induced by IFN-␣-It has been shown that PML regulates apoptotic pathways and induces caspase activation (34, 35) . Therefore, we analyzed the expression of 96 genes involved in the transduction or inhibition of apoptotic stimuli in vector-and EVI1-SiHa cells treated with IFN-␣. We used a commercially available cDNA panel and Northern blot hybridization as described under "Experimental Procedures." We found no difference in the expression of pro-apoptotic genes irrespective of EVI1 expression (data not shown). One of the last steps in the apoptotic pathway is the activation and cleavage of pro-caspase-3. To determine whether EVI1 affects the activation of caspases, vector-and EVI1-SiHa cells were treated with IFN-␣ and harvested each day for 6 days. After this time, the vector-SiHa cells appeared dead, as expected. However, as noted with the primary BM cells (Table I) completely protected the cells from death. Cell lysates were prepared each day for 6 days and the lysates were used for Western blot analysis. The results show that the cleavage of caspase-3 appears noticeable in vector cells after 5-6 days of IFN-␣ treatment (Fig. 4A) and is inhibited by addition of the caspase-3 inhibitor Z-VAD (Fig. 4B) . However, no activation occurs in cells that express EVI1 in the absence (Fig. 4C) or presence (Fig. 4D ) of Z-VAD. It should be noted that similar results (i.e. continued proliferation in presence of IFN-␣, resistance to IFN-induced apoptosis, normal activation of an identical panel of 96 apoptotic genes, and lack of caspase-3 activation after IFN-␣ treatment) were reported for PmlϪ/Ϫ cells treated with IFN-␣ (34). These cells also are resistant to IFN-␣ effects (34) . It was suggested that the resistance of these cells to IFN-␣ was caused by loss of Pml-dependent apoptosis (34) . Our findings are similar to those reported for PmlϪ/Ϫ cells and suggest that EVI1 protects the cells against IFN-induced apoptosis by abrogation of PML induction.
The Position of the ISRE Consensus Determines the Promoter Response to IFN-␣ in the Presence of EVI1-A key question that
arises from the previous results is why, in response to IFN-␣, EVI1 affects the PML promoter differently from that of other ISGs. To answer this question we aligned the promoter of several ISGs including PML (data not shown). Two differences were noted in the promoter of all the genes we tested and compared with PML: first, as previously reported (33) the ISRE consensus of PML is unique and divergent from that of other ISGs. Second, we found that while in all the genes we tested, except for PML, the position of the ISRE is upstream of the transcription start site, in the PML promoter the ISRE is located within the first exon in both mouse and man (33) . To determine whether EVI1 blocks IFN induction of PML by inhibiting selectively the interaction of the ISGF3 complex with the unique PML ISRE, nuclear extracts of vector-or EVI1-SiHa cells cultured in the absence or presence of IFN-␣ were used to perform EMSA as described earlier. The DNA probe was a double-stranded oligomer that spans the unique ISRE sequence of PML located in the first exon of the gene (33) . As expected, when we used nuclear extracts of cells responsive to IFN-␣ we noted a shift in the migration of the probe (Fig 5A, lane 2) . EVI1 alone does not noticeably bind to the probe (Fig. 5A, lane 3) . We also found that, as for the canonical ISRE, EVI1 does not block the formation of the ISGF3-DNA complex that is necessary to gene activation. On the contrary, a more intense slow migrating band was again consistently observed (Fig. 5A, lane 4) . Because EVI1 does not preclude the interaction of the ISGF3 complex with the PML divergent ISRE, we hypothesized that the position of the ISRE within the first exon could be involved in the repression of PML when EVI1 is expressed. To determine whether this hypothesis is correct, we used 200 base pairs (bp) of the human wild type (WT) PML promoter cloned in a promoter-less luciferase reporter vector (WT PML promoter, from nucleotide Ϫ157 to nucleotide ϩ58, Fig. 5A ) in reporter gene assays. This promoter contains the ISRE and flanking nucleotides in their normal position (ϩ31 to ϩ58 of the first exon, Fig. 5B , ISRE sequence is shown in bold). We also constructed a mutant PML promoter in which 28 bp including the ISRE and flanking nucleotides from nucleotides ϩ31 to ϩ58 were removed in their entirety and placed in their entirety 5Ј to nucleotide Ϫ157 (PML-ISRE promoter, Fig. 5B ). The construction of these plasmids is detailed under "Experimental Procedures." NIH-3T3 cells were transiently co-transfected with the WT PML promoter or the mutant PML-ISRE promoter and with vector or EVI1 plasmids and maintained in the presence or absence of IFN-␣ (5000 units/ml). As expected, in the EVI1-negative cells transfected with the WT promoter and treated with IFN-␣ there was a significant activation of the reporter gene (Fig. 5C, bars 1 and 2) . This activation was insignificant in EVI1-positive cells (Fig. 5C, lanes 3 and 4) . Repositioning of the ISRE consensus from the first exon to well upstream of the transcription start site did not impair the ability of the promoter to respond properly to IFN-␣ in the absence of EVI1 and the activation of the reporter gene was essentially identical for the WT and mutated promoters (Fig. 5, C and D, lanes 1 and 2) . However, this repositioning of the ISRE consensus had a drastic effect when EVI1 was co-expressed in the cells because it completely removed the repression to the IFN-␣ response that was observed with the WT promoter (Fig. 5D, lanes 3 and 4) . These results strongly suggest that the position of the ISRE has a critical role in the IFN response of a promoter when EVI1 is expressed. To confirm this result, we performed the complementary experiment with the promoter of the ISG15 gene that responds to IFN-␣ in the presence of EVI1 (Fig. 2) . We moved 36 bp containing the ISRE and flanking nucleotides from their normal position upstream of the transcription start site (WT ISG15 promoter, nucleotides Ϫ121 to Ϫ86, Fig. 6A, top) to downstream of the transcription start site (ISG15 promoter ISRE, Fig. 6A, bottom) , resulting in an organization similar to that of the WT PML (Fig. 5B) . The sequence of the 36 bp is shown in Fig. 6A and the ISRE is indicated with bold letters. NIH-3T3 cells were transiently co-transfected with the WT ISG15 promoter or the mutant ISG15 promoter ISRE and with vector or EVI1 plasmids in the presence or absence of IFN-␣ (5000 units/ml). As expected, in the cells transfected with the WT promoter there was significant reporter gene activation after IFN-␣ treatment (Fig. 6B, lanes 1 and 2) . In agreement with the results of RT-PCR assays and Northern blot analyses (Fig. 2) , significant reporter gene activation was also observed in the presence of EVI1 after IFN-␣ treatment (Fig. 6B, lanes 3  and 4) . However, when the mutant promoter was used, the results were strikingly different. Whereas in the absence of EVI1 the mutant promoter was activated by IFN-␣ as strongly as the WT promoter (compare Fig. 6, B and C, lanes 1 and 2) , the repositioning of the ISRE to the first exon completely abrogated the activation of the reporter gene when EVI1 was co-expressed (Fig. 6C, lanes 3 and 4) . These results confirm that the position of the ISRE within the first exon of PML (or another gene) is responsible for the transcriptional block of the gene in the presence of EVI1 despite overall gene induction by IFN-␣. It should be noted that the PML and ISG15 ISRE consensus sequences are not identical and that the flanking nucleotides that have been repositioned in the two mutant promoters are highly divergent as shown below. There is no significant homology between the sequences that were moved aside from short stretches within the ISREs themselves (shown in bold). Therefore, it is unlikely that the PML activation after repositioning of the sequence is caused by the disruption of the binding of an unknown repressor induced by EVI1. 1 and 2) or the EVI1-expressing plasmid (bars 3 and 4) in the absence (bars 1 and 3) or presence (bars 2 and 4) of IFN-␣ (5,000 units/ml) for 7 h. In the absence of EVI1, IFN-␣ induces activation of the mutant promoter (bars 1 and 2) . The level of activation is comparable with that observed for the WT promoter (C, bars 1 and 2). However, when EVI1 is expressed the repression of the promoter is not observed any longer and there is gene activation at a level comparable with that observed in EVI1-negative cells (bars 2 and 4).
EVI1 Prolongs STAT1 Phosphorylation and DNA Binding of ISGF3 and the Activation of an IFN-inducible Reporter Gene-
The previous results show that for two separate IFN-responsive promoters the position of the ISRE is critical in determining the promoter response when EVI1 is expressed. However, this finding by itself does not explain the mechanism by which EVI1 selectively inhibits the response to IFN-␣ only when the ISRE is located downstream of the transcription start site. In the EMSA with the ISG15 and PML ISRE probes we consistently observed a band more intense with EVI1-positive cells than with the control cells even though the same amount of protein was used in the probe-binding reaction (Figs. 1D and  5A, lanes 2 and 4) . We thought that perhaps the increased intensity of the bands could indicate that an effect of EVI1 is the enhancement of the probe-DNA interaction by stabilization of the ISGF3 complex or other ways. To determine whether this hypothesis is correct, we used an ELISA to analyze the time course of ISGF3-probe binding after IFN-␣ withdrawal. The ELISA is based on antibody recognition of a specific epitope of STAT1 that is accessible only when STAT1 is bound to the target DNA as part of the ISGF3 complex. Vector-or EVI1-SiHa cells were treated with IFN-␣ for 1 h, washed, and incubated with fresh medium. Every hour for 8 h the cells were collected and lysed and the quantified extracts were used for ELISA. In general, activation of ISGF3 lasts about 4 -5 h after removal of IFN-␣. As expected, we found that in vector-SiHa cells the response disappeared after this time (Fig. 7A, empty  circles) . However, in the presence of EVI1 the level of ISGF3 activation was still significantly high after 8 h (Fig. 7A,  black squares) .
To determine whether the prolonged activity of ISGF3 could signify a longer induction of an IFN-responsive promoter, we carried out reporter gene assays of transiently transfected NIH-3T3 cells treated with IFN-␣. After removal of the cytokine, the cells were maintained in culture for 1 to 8 h as described for the ELISA. We used the mutant PML promoter-ISRE as reporter. The results show that in the absence of EVI1, the reporter gene was activated for about 5 h after IFN-␣ treatment (Fig. 7B, white bars) . However, in the presence of EVI1 there was a significantly longer induction that lasted for at least 8 h (Fig. 7B, black bars) . Fig. 2A, EVI1 does not block the activation of this promoter in response to IFN-␣ and the activation is comparable with that observed in the absence of EVI1 (lanes 2 and 4) . C, NIH-3T3 cells were transiently co-transfected with a reporter gene containing the mutant ISG15-ISRE promoter and either the empty vector (bars 1 and 2) or the EVI1-expressing plasmid (bars 3 and 4) in the absence (bars 1 and 3) or presence (bars 2 and 4) of IFN-␣ (5,000 units/ml) for 7 h. In the absence of EVI1, IFN-␣ induces activation of the mutant promoter (bars 1 and 2) . The level of activation is comparable with that observed for the WT promoter (B, bars 1 and 2). However, when the ISRE is moved from its normal position to the first exon of the gene, EVI1 represses the promoter (bars 2 and 4).
FIG. 7. EVI1 prolongs STAT1 phosphorylation.
A, vector (empty circle) and EVI1-SiHa (black square) cells were treated with IFN-␣ (5,000 units/ml) for 1 h, washed, and cultured with fresh Dulbecco's modified Eagle's medium for the indicated times. At each hour for 8 h, cells were collected and lysed. Quantified amounts of protein extracts were used for ELISA as described under "Experimental Procedures." IFN-␣ induces phosphorylation of STAT1, activation of the ISGF3, and binding to the DNA consensus site. The activation was read as optical density at 450 nm. This effect lasts for about 5 h. However, in the presence of EVI1 (black squares) the activation and binding to the DNA is prolonged to at least 8 h, which is the last time point measured. B, EVI1 prolongs ISGF3 activity. NIH-3T3 cells were transiently co-transfected in duplicate with a reporter gene containing the mutant PML-ISRE promoter and either the empty vector (white bars) or the EVI1-expressing plasmid EVI1 (black bars) and cultured with IFN-␣. The cells were washed, and maintained in IFN-free Dulbecco's modified Eagle's medium for the indicated times. At each hour for 8 h, duplicate plates of cells were collected, the cells were lysed, and the expression of luciferase was measured. IFN-␣ induces the activation of the mutant PML promoter in the absence and presence of EVI1. The activation in the absence of EVI1 lasts about 5 h. However, in the presence of EVI1 the activation is prolonged to at least 8 h, which is the last time point we measured.
DISCUSSION
IFNs are a family of cytokines that control several cellular functions, repress proliferation, and induce apoptosis in a variety of cell types (26, 27) . We show here that the antiproliferative and apoptotic effects of IFN-␣ are completely abrogated in cell lines and primary hematopoietic cells by the forced expression of the oncogenic protein EVI1. The classic signaling pathway of IFN-␣ requires phosphorylation of STAT1, assembly of phosphorylated STAT1 into the ISGF3 complex, and nuclear translocation and DNA binding of ISGF3 to activate tissue-specific sets of ISGs. We show that in EVI1-expressing cells all these steps occur correctly and that genes are activated as expected in response to IFN-␣. The only exception among the genes we tested is PML, which is not induced by IFN-␣ as expected when EVI1 is expressed. PML is the central component of the PML nuclear bodies, which represent nuclear structures implicated in the regulation of a variety of cellular processes, including tumor suppression and apoptosis. In primary cells and cell lines, these nuclear bodies increase in number and size upon exposure to IFN-␣ (31, 32). However, they are not observed in PmlϪ/Ϫ murine cells (34) , which like EVI1-positive cells, are IFN-resistant (34) . It was established that in these PmlϪ/Ϫ cells, the anti-proliferative and apoptotic pathways induced in response to IFN-␣ are blocked, supporting the notion that Pml up-regulation plays a key role in the control of these processes (34, 35) . We find that EVI1 abrogates IFN activation of PML and PML bodies and that it blocks IFN-␣ effects. Thus, by analogy to PmlϪ/Ϫ cells, we propose that the major IFN-suppressive effect of EVI1 is the ability to inhibit Pml induction and the pathways that are induced and regulated by this protein in response to IFN-␣.
The mechanism of Pml inhibition is more difficult to define because the effects of EVI1 on IFN-␣ response seem contradictory. On the one hand, our results clearly show that EVI1 actually prolongs the effects of IFN-␣ measured as functional activity of ISGF3 and reporter gene activation. On the other hand, there is no doubt that despite this enhancement, EVI1 completely protects cell lines and primary cells of different histology from the growth suppression and apoptosis that are a marker of IFN-␣. One could argue that EVI1 activates an unknown repressor that specifically inhibits the PML response. However, results of repositioning the PML ISRE from its normal location to an alternative site upstream of the transcription start site suggests that this model is unlikely and would rather support that the position of the ISRE itself is the most critical factor in the anomalous response of PML. This possibility is further backed by the results of the inverse experiment involving the translocation of the ISG15 ISRE from its normal site to the first exon of the gene and by the lack of significant homology between the repositioned regions of the PML and ISG15 ISRE.
Perhaps a clue to a potential mechanism of inhibition by EVI1 could be found in the consistently more intense ISGF3-DNA bands observed in EMSA of EVI1-positive cells. These results combined with those of ELISA show that in EVI1-positive cells the ISGF3 activity and DNA binding persist longer. Potentially, a prolonged DNA occupancy by the ISGF3 complex could result in inefficient elongation of the PML transcript if the ISRE is within the transcribed region. Transcriptional control at the level of elongation is not unusual and a block to nascent RNA chain elongation, causing attenuation of transcription, is an important regulatory mechanism controlling the steady-state levels of several RNAs. It was shown in various situations for c-MYC, and in one case for c-FOS, that these genes can be down-regulated by a block to elongation of nascent RNA chains. Expression of c-MYC mRNA appears to be dependent on both promoter activity and attenuator function and interference at multiple points with this complex regulatory process appears to be an important mechanism by which small-cell lung cancer and other human tumors evade growth control (45, 46) . In another instance, the relative rates of transcription of the human adenosine deaminase (ADA) gene were determined in isolated nuclei from T and B cells and fibroblasts. It was reported that in addition to transcription initiation being the major control mechanism of steady-state ADA mRNA in all cell lines, first intron elongation pausing occurs specifically in fibroblasts (47) , indicating that processes affecting the elongation of nascent transcripts into completed primary transcripts play a role in the tissue-specific expression of the gene. Finally, another example is that of the proto-oncogene c-MYB. High levels of c-MYB expression are necessary for the proliferation of hematopoietic precursor cells, whereas down-regulation of c-MYB is required for terminal differentiation. This down-regulation occurs through a conditional block to transcription elongation in intron I. By using EMSA with different segments of the first intron as probe, it was shown that a specific probe containing the DNA binding site for the interferon regulatory factor 1 (IRF-1) was generated and that the activity of a reporter gene driven by a c-MYB promoter containing the entire intron 1 was suppressed upon IRF-1 expression (48) . Together, these results are consistent with the existence of a functional relationship between specific constitutive or inducible factors and negative regulation of expression at the transcriptional level by a mechanism that depends on the interaction of the factor with a segment of the gene implicated in transcription pausing. It is quite likely that there are other IFN-responsive genes like PML that have their ISRE downstream of the promoter. It is also very possible that these genes are involved in the IFN-dependent control of proliferation and apoptosis. Given the results with the mutant ISG15 promoter we predict that as in PML these putative genes are also unresponsive to IFN-␣ when EVI1 is expressed.
Finally, it was recently reported on the critical role that ISGylation plays in the normal response of a cell to type I IFN (49) . ISGylation involves the conjugation of ISG15, an ubiquitin-like modifier, to a protein. As with other protein modifiers, many proteins including STAT1 are substrates for ISGylation. The equilibrium between ISGylated and non-ISG15-modified proteins requires the activity of an ISG15-specific protease, UPB43, which belongs to the family of ubiquitinspecific proteases (49) . Cells with a biallelic mutation of Ubp43 have a profound increase in the level of protein ISGylation, and are hypersensitive to type I IFN and undergo apoptosis upon IFN-␣ treatment (49) . These cells have therefore the opposite reaction to IFN-␣ than the EVI1-positive cells. Based on the results we obtained by re-positioning the ISRE in two different promoters, it is unlikely that the level of ISG15 and ISGylation is altered by the expression of EVI1. However, this recent report by Malakhova et al. (49) and our studies show that the correct modulation of the many effects of IFN-␣ occurs at many levels and depends on many factors that include not only protein modification but also the position of the ISRE and the life-time of STAT1 phosphorylation and ISGF3 complex. Whereas the combined work of many outstanding investigators is slowly decoding the complex signaling network leading to cell response to IFN, much less is known about the opposite pathways that regulate the shutting down of this response and the return of the cell to the basal level. Thus, at this time it is difficult to predict at which level EVI1 affects the de-activation of the IFN response. However, given the delicate balance of gene expression that must be maintained in cells exposed to IFN-␣ it is not surprising that the regulation of IFN-␣ response is so complex.
